Novartis
Precision Oncology Drugmakers Are the IRA's Staunchest Adversaries—And They're Not Backing Down
Premium
Medicare price negotiations officially began this week, but drugmakers are determined to challenge the law's constitutionality in front of the highest court.
The company behind the patient-facing app just inked a deal with Labcorp to educate patients around biomarker testing including for HER2-low breast cancer.
Novartis to Pursue Regulatory Filing for Lutathera After Positive Data in First-Line GEP-NETs
The targeted radiopharmaceutical plus octreotide improved patients' progression-free survival more than octreotide alone in the Phase III NETTER-2 clinical trial.
Novartis Stops Developing Geographic Atrophy Gene Therapy Acquired From Syncona
Because of the decision, Syncona will write off $68.3 million in potential milestone payments that it was eligible for under a 2022 acquisition deal.
Becton Dickinson, Navigate BioPharma Collaborate on Flow Cytometry Companion Diagnostics Development
The partners will offer their combined expertise to biopharma companies developing diagnostics and clinical decision-making tools.